Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”: Thromb Haemost 2014; 112: 841

Thrombosis and Haemostasis

Volumn 112, Issue 4, 2014, Pages 842-

  Husted, Steen ^a   Lip, Gregory Y H ^b   On behalf of the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease, ^c  

^a REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN ETEXILATE; GLUTAMIC ACID; NON VITAMIN K ANTAGONIST; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; BLOOD CLOTTING FACTOR;

BLEEDING; CARBOXYLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HEART ATRIUM FIBRILLATION; HUMAN; NOMENCLATURE; NOTE; SEARCH ENGINE; LIVER DISEASES; METABOLISM; RENAL INSUFFICIENCY; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HUMANS; LIVER DISEASES; RENAL INSUFFICIENCY; THROMBOEMBOLISM;

EID: 84908552193     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0564     Document Type: Note

References (5)

1. Ansell J, Crowther M, Burnett A, et al. Letter to the Editor. Thromb Haemost 2014; 112: 841.
2. Lip GYH, Camm J, Hylek EM, et al. Non-vitamin K antagonist oral anticoagulants. An appeal for concensus on terminology. Chest 2014; 145: 1177-1178.
3. Majeed A, Hwang HG, Connolly SJ, et al Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
4. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
5. De Caterina R, Husted S, Wallentin L, et al.; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.